Sprinting for A+H listing, raising more than 12.5 billion yuan, this week's IPO pharmaceutical companies are concerned
)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC)
Voice of China｜Toripalimab may become a new treatment option for dMMR/MSI-H colorectal cancer
Clin Gastroenterology H: Effects of Domperidone Treatment on Gastroparesis Symptoms
Clin Gastroenterology H: Perianal Crohn's disease associated with poor disease prognosis
Clin Gastroenterology H: PNPLA3 polymorphism reduces susceptibility to diabetes in patients with nonalcoholic fatty liver disease
Clin Gastroenterology H: Association of body weight change with changes in histological features and blood markers in nonalcoholic steatohepatitis
"Super dark horse" Rongchang Bio is about to launch A+H. What is the internal engine?
Russia's pollock raw material production plummeted, Norebo no longer exports H&G to China
Gut: How effective is H. pylori eradication therapy in functional dyspepsia?
Clin Gastroenterology H: Using a low-FODMAP diet in irritable bowel syndrome improves bowel movements
Clin Gastroenterology H: COVID-19 vaccine is effective in patients with inflammatory bowel disease and is not associated with disease exacerbation
The output is 10360Nm3/h!
Cases Shenghui | MSI-H advanced colon cancer patients achieved CR after 1 year of nvolizumab treatment!
Clin Gastroenterology H: Correlation between risk of inflammatory bowel disease and disease phenotype
effect in the treatment of MSI-H/dMMR endometrial cancer patients
Clin Gastroenterology H: Association of Physical Activity with Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in NAFLD Patients
Clinical Gastroenterology H: Plasminogen activator inhibitor-1 can be used as a marker for changes
Clinical Gastroenterology H: Biological agents will not increase the risk of cancer recurrence